Exchange Session 1 – Explore
Review medications for opioid use disorders (MOUD), with a focus on buprenorphine treatment and its various formulations, and strategies for including harm reduction approaches into care. Discuss administrative, clinical and financial considerations, and provide resources for both prescribers and non-prescribers.
AOAAM Half and Half Training
AOAAM Half and Half Training
PCSS-MOUD Half and Half Training
PCSS-MOUD Half and Half Training
Please email: [email protected] to register for the training.
Treating Adolescents with Substance Use Disorder
Target Audience: This activity was developed to meet the needs of physicians, nurses and interprofessional healthcare providers. Discussion is designed to promote interactivity through an informal “round table” conversation. Attendees will be given the opportunity to speak directly with the presenter to ask questions and discuss issues. In support of improving patient care, American Academy […]
Enhance Personalized Treatment
Target Audience: This activity was developed to meet the needs of physicians and interprofessional healthcare providers. Discussion is designed to promote interactivity through an informal “round table” conversation. Attendees will be given the opportunity to speak directly with the presenter to ask questions and discuss issues. In support of improving patient care, American Academy of […]
AOAAM Half and Half MOUD Training
Please reach out to AOAAM for any questions regarding this training at [email protected].
Exchange Session 4 – Implement/Sustain
Consider approaches to sustain MOUD and ensure continued access to high-quality care for our most challenged patients, including those who are pregnant, youth/adolescents, those with acute or chronic pain, and those electing to taper their dose.
Exchange Session 3 – Implement/Sustain
Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.
